Literature DB >> 35788344

Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality.

Chun-Han Lo1, Peiyun Ni2, Yan Yan3, Wenjie Ma4, Amit D Joshi4, Long H Nguyen5, Raaj S Mehta5, Paul Lochhead4, Mingyang Song6, Gary C Curhan7, Yin Cao8, Andrew T Chan9.   

Abstract

BACKGROUND & AIMS: The use of proton pump inhibitors (PPIs) has increased rapidly in the past 2 decades. Concerns about the regular use of PPIs contributing to mortality have been raised.
METHODS: We conducted a prospective cohort study using data collected from the Nurses' Health Study (2004-2018) and the Health Professionals Follow-up Study (2004-2018). Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% CIs for mortality according to PPI use. We used a modified lag-time approach to minimize reverse causation (ie, protopathic bias).
RESULTS: Among 50,156 women and 21,731 men followed for 831,407 person-years and a median of 13.8 years, we documented 22,125 deaths, including 4592 deaths from cancer, 5404 from cardiovascular diseases, and 12,129 deaths from other causes. Compared with nonusers of PPIs, PPI users had significantly higher risks of all-cause mortality (HR, 1.19; 95% CI, 1.13-1.24) and mortality due to cancer (HR, 1.30; 95% CI, 1.17-1.44), cardiovascular diseases (HR, 1.13; 95% CI, 1.02-1.26), respiratory diseases (HR, 1.32; 95% CI, 1.12-1.56), and digestive diseases (HR, 1.50; 95% CI, 1.10-2.05). Upon applying lag times of up to 6 years, the associations were attenuated and no longer statistically significant (all-cause: HR, 1.04; 95% CI, 0.97-1.11; cancer: HR, 1.07; 95% CI, 0.89-1.28; cardiovascular diseases: HR, 0.94; 95% CI, 0.81-1.10; respiratory diseases: HR, 1.20; 95% CI, 0.95-1.50; digestive diseases: HR, 1.38; 95% CI, 0.88-2.18). Longer duration of PPI use did not confer higher risks for all-cause and cause-specific mortality.
CONCLUSIONS: After accounting for protopathic bias, PPI use was not associated with higher risks of all-cause mortality and mortality due to major causes.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antacid; Death; Epidemiology; GERD; Medication

Mesh:

Substances:

Year:  2022        PMID: 35788344      PMCID: PMC9509450          DOI: 10.1053/j.gastro.2022.06.067

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   33.883


  40 in total

1.  The use of a self-administered questionnaire to assess diet four years in the past.

Authors:  W C Willett; L Sampson; M L Browne; M J Stampfer; B Rosner; C H Hennekens; F E Speizer
Journal:  Am J Epidemiol       Date:  1988-01       Impact factor: 4.897

2.  Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Authors:  Paul Moayyedi; John W Eikelboom; Jackie Bosch; Stuart J Connolly; Leanne Dyal; Olga Shestakovska; Darryl Leong; Sonia S Anand; Stefan Störk; Kelley R H Branch; Deepak L Bhatt; Peter B Verhamme; Martin O'Donnell; Aldo P Maggioni; Eva M Lonn; Leopoldo S Piegas; Georg Ertl; Matyas Keltai; Nancy Cook Bruns; Eva Muehlhofer; Gilles R Dagenais; Jae-Hyung Kim; Masatsugu Hori; P Gabriel Steg; Robert G Hart; Rafael Diaz; Marco Alings; Petr Widimsky; Alvaro Avezum; Jeffrey Probstfield; Jun Zhu; Yan Liang; Patricio Lopez-Jaramillo; Ajay K Kakkar; Alexander N Parkhomenko; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Dragos Vinereanu; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; Kaj P Metsarinne; Keith A A Fox; Salim Yusuf
Journal:  Gastroenterology       Date:  2019-05-29       Impact factor: 22.682

3.  Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.

Authors:  Yan Xie; Benjamin Bowe; Tingting Li; Hong Xian; Sumitra Balasubramanian; Ziyad Al-Aly
Journal:  J Am Soc Nephrol       Date:  2016-04-14       Impact factor: 10.121

4.  Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.

Authors:  Derk C F Klatte; Alessandro Gasparini; Hong Xu; Pietro de Deco; Marco Trevisan; Anna L V Johansson; Björn Wettermark; Johan Ärnlöv; Cynthia J Janmaat; Bengt Lindholm; Friedo W Dekker; Josef Coresh; Morgan E Grams; Juan J Carrero
Journal:  Gastroenterology       Date:  2017-06-02       Impact factor: 22.682

Review 5.  The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.

Authors:  Daniel E Freedberg; Lawrence S Kim; Yu-Xiao Yang
Journal:  Gastroenterology       Date:  2017-03       Impact factor: 22.682

6.  Effect of Proton Pump Inhibitors on Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis.

Authors:  Tsung-Hsing Hung; Chih-Wei Tseng; Hsing-Feng Lee; Chih-Chun Tsai; Chen-Chi Tsai
Journal:  Ann Hepatol       Date:  2018-10-16       Impact factor: 2.400

7.  Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study.

Authors:  Tony Antoniou; Erin M Macdonald; Simon Hollands; Tara Gomes; Muhammad M Mamdani; Amit X Garg; J Michael Paterson; David N Juurlink
Journal:  CMAJ Open       Date:  2015-04-02

8.  Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis.

Authors:  Silvia Nardelli; Stefania Gioia; Lorenzo Ridola; Alessio Farcomeni; Manuela Merli; Oliviero Riggio
Journal:  Hepatology       Date:  2019-03-04       Impact factor: 17.425

9.  Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study.

Authors:  Brittany M Charlton; Janet W Rich-Edwards; Graham A Colditz; Stacey A Missmer; Bernard A Rosner; Susan E Hankinson; Frank E Speizer; Karin B Michels
Journal:  BMJ       Date:  2014-10-31

10.  Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults.

Authors:  Jan Zirk-Sadowski; Jane A Masoli; Joao Delgado; Willie Hamilton; W David Strain; William Henley; David Melzer; Alessandro Ble
Journal:  J Am Geriatr Soc       Date:  2018-04-20       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.